Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The company has raised US$4.5 million in funding for its AI operating system
This product will be manufactured at Lupin’s Pithampur facility in India
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Subscribe To Our Newsletter & Stay Updated